EUVIMEDEUVIMED entdecken
Crossref

Factors Affecting the Ability to Discontinue Oral Corticosteroid Use in Patients with EGPA Treated with Anti-Interleukin-5 Therapy

Osamu Matsuno

International Archives of Allergy and Immunology · 2024

DOI: 10.1159/000533535 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Archives of Allergy and Immunology, 2024. Verfasst von Osamu Matsuno. Beteiligte Einrichtung: Department of Allergic and Rheumatoid Disease, Osaka Habikino Medical Center, Habikino, Japan. Hauptthemen laut MEDLINE: Churg-Strauss Syndrome, Granulomatosis with Polyangiitis, Asthma, Pulmonary Eosinophilia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Patients with eosinophilic granulomatosis with polyangiitis (EGPA) and some with severe eosinophilic asthma require continuous long-term oral corticosteroid (OCS) treatment for disease control. The anti-interleukin-5 agent, mepolizumab, has recently become available for the treatment of severe eosinophilic asthma and EGPA, with promising results and safety profiles. The proportion of patients with EGPA who discontinued oral steroids was 18% in the MIRRA trial. To compare patients with EGPA who were able to discontinue steroids with mepolizumab with those who could not.

Methods

Twenty patients with EGPA treated with mepolizumab were evaluated at Osaka Habikino Medical Center. The OCS dose, asthma control test score, fractional exhaled nitric oxide levels, peripheral eosinophil count, and spirometric parameters were evaluated before and after treatment.

Results

There was a significant reduction in the mean OCS dose from a prednisolone equivalent of 8.88 ± 4.99 mg/day to 3.18 ± 3.47 mg/day (p < 0.001). In this study, 40% of patients discontinued oral steroids. The most common reason for the failure to discontinue steroids in patients was poor asthma control. The percentage of predicted forced expiratory volume in 1 s significantly improved in patients with EGPA who could discontinue steroids after receiving mepolizumab.

Conclusion

In this real-world study, treatment with mepolizumab for EGPA was associated with a significant reduction in OCS use; however, poor asthma control was identified as an inhibiting factor for steroid reduction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Churg-Strauss SyndromeGranulomatosis with PolyangiitisAsthmaPulmonary EosinophiliaHumansAdrenal Cortex HormonesSteroids

Stichwörter der Autor:innen

AsthmaEosinophilic granulomatosis with polyangiitisForced expiratory volume in 1 sMepolizumabOral corticosteroid

Substanzen

Adrenal Cortex HormonesSteroids

Autor:innen und Institutionen

  • Department of Allergic and Rheumatoid Disease, Osaka Habikino Medical Center, Habikino, Japan.

Zitieren

APA

Matsuno, O. (2024). Factors Affecting the Ability to Discontinue Oral Corticosteroid Use in Patients with EGPA Treated with Anti-Interleukin-5 Therapy. International Archives of Allergy and Immunology. https://doi.org/10.1159/000533535

Vancouver

Matsuno O. Factors Affecting the Ability to Discontinue Oral Corticosteroid Use in Patients with EGPA Treated with Anti-Interleukin-5 Therapy. International Archives of Allergy and Immunology. 2024. doi:10.1159/000533535

BibTeX
@article{Matsuno2024,
  author = {Matsuno, Osamu},
  title = {Factors Affecting the Ability to Discontinue Oral Corticosteroid Use in Patients with EGPA Treated with Anti-Interleukin-5 Therapy},
  journal = {International Archives of Allergy and Immunology},
  year = {2024},
  doi = {10.1159/000533535}
}
Kostenlos starten →